PMID- 30497486
OWN - NLM
STAT- MEDLINE
DCOM- 20190201
LR  - 20190201
IS  - 1476-511X (Electronic)
IS  - 1476-511X (Linking)
VI  - 17
IP  - 1
DP  - 2018 Nov 30
TI  - Fufang-Zhenzhu-Tiaozhi Capsule reduces restenosis via the downregulation of 
      NF-kappaB and inflammatory factors in rabbits.
PG  - 272
LID - 10.1186/s12944-018-0921-3 [doi]
LID - 272
AB  - BACKGROUND: To investigate the effects of a Chinese herbal medicine 
      Fufang-Zhenzhu Tiaozhi Capsule (FTZ) on restenosis and elucidate the mechanism of 
      action. METHODS: A restenosis model was established by balloon rubbing the 
      endothelium of the abdominal aorta followed by high fat diet. Rabbits were 
      divided into blank control group, restenosis group, FTZ group (0.66 mg/kg/day), 
      atorvastatin group (5 mg/kg/day) and FTZ + atorvastatin group (n = 8). Vascular 
      stenosis was analyzed by X-ray. Serum levels of chemokines and cytokines 
      interleukin-1 (IL-1), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-12 
      (IL-12), C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-alpha), monocyte 
      chemoattractant protein-1 (MCP-1), and intercellular adhesion molecule-1 (ICAM-1) 
      were measured by ELISA. The levels of NF-kappaB, IkappaB-alpha, P-IkappaBalpha, IKK-alpha, and P-IKKalpha/beta 
      from injured abdominal arteries were detected by Western blotting. RESULTS: 
      Restenosis was induced successfully via abdominal artery balloon injuries and 
      high fat diet. Restenosis was significantly decreased in FTZ group compared with 
      restenosis group (P < 0.05). FTZ group had markedly reduced serum lipid levels 
      (P < 0.05). In addition, the levels of TNF-alpha, IL-1, IL-6, IL-8, IL-12, ICAM-1 and 
      MCP-1 decreased by FTZ treatment (P < 0.05). The expression of NF-kappaB in the 
      atherosclerotic lesions was significantly attenuated in FTZ group (P < 0.05). 
      CONCLUSION: FTZ could reduce restenosis via reducing NF-kappaB activity and 
      inflammatory factor expression within the atherosclerotic lesion in a rabbit 
      restenosis model. FTZ may be a new therapeutic agent for restenosis.
FAU - Zhang, Rendan
AU  - Zhang R
AD  - Department of Cardiology, Boai Hospital of Zhongshan, Zhongshan, 528403, China.
FAU - Li, Tudi
AU  - Li T
AD  - Department of Cardiology, The First Affiliated Hospital of Guangdong 
      Pharmaceutical University, Guangzhou, 510080, Guangdong, China.
FAU - Guo, Jiao
AU  - Guo J
AD  - Department of Cardiology, The First Affiliated Hospital of Guangdong 
      Pharmaceutical University, Guangzhou, 510080, Guangdong, China.
FAU - Zhao, Yanqun
AU  - Zhao Y
AD  - Department of Cardiology, The First Affiliated Hospital of Guangdong 
      Pharmaceutical University, Guangzhou, 510080, Guangdong, China.
FAU - Liu, Yuhong
AU  - Liu Y
AD  - Department of Cardiology, The First Affiliated Hospital of Guangdong 
      Pharmaceutical University, Guangzhou, 510080, Guangdong, China.
FAU - Yao, Yusi
AU  - Yao Y
AD  - Department of Cardiology, The First Affiliated Hospital of Guangdong 
      Pharmaceutical University, Guangzhou, 510080, Guangdong, China.
FAU - Zeng, Zhihuan
AU  - Zeng Z
AD  - Department of Cardiology, The First Affiliated Hospital of Guangdong 
      Pharmaceutical University, Guangzhou, 510080, Guangdong, China. gzzh@163.com.
LA  - eng
PT  - Journal Article
DEP - 20181130
PL  - England
TA  - Lipids Health Dis
JT  - Lipids in health and disease
JID - 101147696
RN  - 0 (Chemokine CCL2)
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (Interleukin-1)
RN  - 0 (Interleukin-6)
RN  - 0 (Interleukin-8)
RN  - 0 (NF-kappa B)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 187348-17-0 (Interleukin-12)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - A0JWA85V8F (Atorvastatin)
SB  - IM
MH  - Animals
MH  - Aorta, Abdominal/drug effects
MH  - Atherosclerosis/*drug therapy/genetics/physiopathology
MH  - Atorvastatin
MH  - C-Reactive Protein/genetics
MH  - Chemokine CCL2/genetics
MH  - Coronary Restenosis/*drug therapy/genetics/physiopathology
MH  - Diet, High-Fat/adverse effects
MH  - Disease Models, Animal
MH  - Drugs, Chinese Herbal/*administration & dosage
MH  - Endothelium/drug effects/physiopathology
MH  - Gene Expression Regulation/drug effects
MH  - Humans
MH  - Inflammation/*drug therapy/genetics/physiopathology
MH  - Interleukin-1/genetics
MH  - Interleukin-12/genetics
MH  - Interleukin-6/genetics
MH  - Interleukin-8/genetics
MH  - NF-kappa B/genetics
MH  - Rabbits
MH  - Tumor Necrosis Factor-alpha/genetics
PMC - PMC6267089
OTO - NOTNLM
OT  - Animal model
OT  - FTZ
OT  - Inflammation
OT  - NF-kappaB
OT  - Restenosis
COIS- ETHICS APPROVAL: All animal procedures were performed in accordance with the 
      protocols approved by the Committee for Supervision of Animal Experiments of 
      Guangdong Pharmaceutical University (Guangzhou, China). CONSENT FOR PUBLICATION: 
      Not applicable. COMPETING INTERESTS: The authors declare that they have no 
      competing interests. PUBLISHER'S NOTE: Springer Nature remains neutral with 
      regard to jurisdictional claims in published maps and institutional affiliations.
EDAT- 2018/12/01 06:00
MHDA- 2019/02/02 06:00
PMCR- 2018/11/30
CRDT- 2018/12/01 06:00
PHST- 2018/09/21 00:00 [received]
PHST- 2018/11/20 00:00 [accepted]
PHST- 2018/12/01 06:00 [entrez]
PHST- 2018/12/01 06:00 [pubmed]
PHST- 2019/02/02 06:00 [medline]
PHST- 2018/11/30 00:00 [pmc-release]
AID - 10.1186/s12944-018-0921-3 [pii]
AID - 921 [pii]
AID - 10.1186/s12944-018-0921-3 [doi]
PST - epublish
SO  - Lipids Health Dis. 2018 Nov 30;17(1):272. doi: 10.1186/s12944-018-0921-3.